Novo Nordisk

News

Lilly holds off on tirzepatide filing in obesity, waiting fo...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

News

Novo Nordisk achieve headline results with icodec insulin

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 pha

News

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other di

Views & Analysis

Lilly’s Mounjaro wins latest head-to-head battle in clinical...

Diabetes is one of the most common health conditions in the United States, afflicting more than 11% of the population, with over 90% included in the type 2 category.

Digital

Health Innovators – Matt Dugan

Pharmaphorum Editor-in-Chief Jonah Comstock welcomes Matt Dugan, director and head of innovation at Novo Nordisk, to discuss the company’s digital transformation journey.

News

Novo Nordisk, Kry partner on digital programme for obesity

Digital health specialist Kry has teamed up with pharma group Novo Nordisk on the development of resources that can help people with obesity manage their condition and adhere to treatment.

Lilly holds off on tirzepatide filing in obesity, waiting fo...

Novo Nordisk achieve headline results with icodec insulin

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Lilly’s Mounjaro wins latest head-to-head battle in clinical...

Health Innovators – Matt Dugan

Novo Nordisk, Kry partner on digital programme for obesity

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks